Ge Healthcare Technologies Inc. (GEHC)

$86.72

+0.48

(+0.56%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Ge Healthcare Technologies Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 4.70B → 5.20B (in $), with an average increase of 3.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 375.0M → 403.0M (in $), with an average increase of 7.0% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 49.4% return, outperforming this stock by 42.1%

Performance

  • $85.90
    $87.24
    $86.72
    downward going graph

    0.95%

    Downside

    Day's Volatility :1.54%

    Upside

    0.6%

    downward going graph
  • $62.28
    $94.43
    $86.72
    downward going graph

    28.18%

    Downside

    52 Weeks Volatility :34.05%

    Upside

    8.16%

    downward going graph

Returns

PeriodGe Healthcare Technologies Inc.Index (NASDAQ Composite)
3 Months
20.53%
1.2%
6 Months
33.35%
22.4%
1 Year
-1.77%
33.0%
3 Years
42.57%
12.0%

Highlights

Market Capitalization
39.4B
Book Value
$15.67
Dividend Share
0.12
Dividend Yield
0.14%
Earnings Per Share (EPS)
3.04
PE Ratio
28.4
PEG Ratio
20.11
Wall Street Target Price
95.71
Profit Margin
8.02%
Operating Margin TTM
16.27%
Return On Assets TTM
6.15%
Return On Equity TTM
19.15%
Revenue TTM
19.6B
Revenue Per Share TTM
42.97
Quarterly Revenue Growth YOY
5.4%
Gross Profit TTM
7.2B
EBITDA
3.6B
Diluted Eps TTM
3.04
Quarterly Earnings Growth YOY
-0.28
EPS Estimate Current Year
4.3
EPS Estimate Next Year
4.84
EPS Estimate Current Quarter
1.07
EPS Estimate Next Quarter
0.91

Analyst Recommendation

Buy
    68%Buy
    31%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Ge Healthcare Technologies Inc.(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
10
Hold
6
5
5
Sell
00
1
1

Analyst Forecast

What analysts predicted

Upside of 10.37%

Current $86.72
Target $95.71

Company Financials

FY19Y/Y Change
Revenue
16.6B
-
Net Income
1.5B
-
Net Profit Margin
9.16%
-
FY20Y/Y Change
Revenue
17.2B
↑ 3.19%
Net Income
2.1B
↑ 35.04%
Net Profit Margin
11.99%
↑ 2.83%
FY21Y/Y Change
Revenue
17.6B
↑ 2.45%
Net Income
2.2B
↑ 9.18%
Net Profit Margin
12.78%
↑ 0.79%
FY22Y/Y Change
Revenue
18.3B
↑ 4.3%
Net Income
1.9B
↓ 14.73%
Net Profit Margin
10.45%
↓ 2.33%
FY23Y/Y Change
Revenue
19.6B
↑ 6.6%
Net Income
3.1B
↑ 62.0%
Net Profit Margin
15.88%
↑ 5.43%
Q3 FY22Q/Q Change
Revenue
4.6B
↑ 2.05%
Net Income
488.0M
↑ 0.62%
Net Profit Margin
10.66%
↓ 0.16%
Q4 FY22Q/Q Change
Revenue
4.9B
↑ 7.91%
Net Income
554.0M
↑ 13.52%
Net Profit Margin
11.22%
↑ 0.56%
Q1 FY23Q/Q Change
Revenue
4.7B
↓ 4.68%
Net Income
372.0M
↓ 32.85%
Net Profit Margin
7.9%
↓ 3.32%
Q2 FY23Q/Q Change
Revenue
4.8B
↑ 2.34%
Net Income
418.0M
↑ 12.37%
Net Profit Margin
8.68%
↑ 0.78%
Q3 FY23Q/Q Change
Revenue
4.8B
↑ 0.1%
Net Income
375.0M
↓ 10.29%
Net Profit Margin
7.78%
↓ 0.9%
Q4 FY23Q/Q Change
Revenue
5.2B
↑ 7.96%
Net Income
403.0M
↑ 7.47%
Net Profit Margin
7.74%
↓ 0.04%
FY20Y/Y Change
Total Assets
24.2B
-
Total Liabilities
9.5B
-
FY21Y/Y Change
Total Assets
26.3B
↑ 8.59%
Total Liabilities
9.6B
↑ 1.64%
FY22Y/Y Change
Total Assets
27.5B
↑ 4.68%
Total Liabilities
18.2B
↑ 88.71%
FY23Y/Y Change
Total Assets
32.5B
↑ 17.85%
Total Liabilities
25.1B
↑ 38.33%
Q3 FY22Q/Q Change
Total Assets
26.1B
↓ 1.5%
Total Liabilities
9.2B
↓ 0.01%
Q4 FY22Q/Q Change
Total Assets
27.5B
↑ 5.65%
Total Liabilities
18.2B
↑ 97.81%
Q1 FY23Q/Q Change
Total Assets
32.6B
↑ 18.51%
Total Liabilities
25.9B
↑ 42.71%
Q2 FY23Q/Q Change
Total Assets
32.3B
↓ 1.0%
Total Liabilities
25.0B
↓ 3.67%
Q3 FY23Q/Q Change
Total Assets
32.4B
↑ 0.22%
Total Liabilities
25.2B
↑ 1.01%
Q4 FY23Q/Q Change
Total Assets
32.5B
↑ 0.22%
Total Liabilities
25.1B
↓ 0.38%
FY19Y/Y Change
Operating Cash Flow
2.0B
-
Investing Cash Flow
-325.0M
-
Financing Cash Flow
-1.6B
-
FY20Y/Y Change
Operating Cash Flow
1.7B
↓ 15.18%
Investing Cash Flow
-323.0M
↓ 0.62%
Financing Cash Flow
-21.5B
↑ 1268.74%
FY21Y/Y Change
Operating Cash Flow
1.6B
↓ 4.74%
Investing Cash Flow
-1.8B
↑ 445.2%
Financing Cash Flow
-263.0M
↓ 98.78%
FY22Y/Y Change
Operating Cash Flow
2.1B
↑ 31.49%
Investing Cash Flow
-398.0M
↓ 77.4%
Financing Cash Flow
-822.0M
↑ 212.55%
Q3 FY22Q/Q Change
Operating Cash Flow
622.0M
↓ 3373.68%
Investing Cash Flow
-118.0M
-
Financing Cash Flow
-505.0M
↓ 460.71%
Q1 FY23Q/Q Change
Operating Cash Flow
468.0M
↓ 55.09%
Investing Cash Flow
-266.0M
-
Financing Cash Flow
673.0M
↓ 1918.92%
Q2 FY23Q/Q Change
Operating Cash Flow
-67.0M
↓ 114.32%
Investing Cash Flow
-84.0M
↓ 68.42%
Financing Cash Flow
-227.0M
↓ 133.73%

Technicals Summary

Sell

Neutral

Buy

Ge Healthcare Technologies Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-2.31%
33.35%
-1.77%
42.57%
42.57%
Solventum Corp
Solventum Corp
-8.1%
-8.1%
-8.1%
-8.1%
-8.1%
Veeva Systems Inc.
Veeva Systems Inc.
-12.34%
1.98%
7.91%
-29.07%
47.16%
Healthequity Inc
Healthequity Inc
0.62%
10.75%
49.37%
4.64%
14.82%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
28.4
28.4
20.11
4.3
0.19
0.06
0.0
15.67
Solventum Corp
Solventum Corp
NA
NA
NA
0.0
0.12
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
61.82
61.82
1.35
4.76
0.13
0.05
NA
28.8
Healthequity Inc
Healthequity Inc
126.86
126.86
2.29
2.19
0.03
0.03
NA
23.63
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$39.4B
42.57%
28.4
8.02%
Solventum Corp
Solventum Corp
NA
$11.7B
-8.1%
NA
16.42%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$32.1B
47.16%
61.82
22.24%
Healthequity Inc
Healthequity Inc
Buy
$7.0B
14.82%
126.86
5.57%

Company Information

ge healthcare (nyse: ge) provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. while we encourage and welcome comments to our linkedin page, these posts from members of the public do not necessarily represent ge healthcare views, and we do not confirm their accuracy or endorse them. ge healthcare is part of highly regulated medical device and pharmaceutical industry. posts and conversations may be removed as a result, but may be forwarded to other people within ge healthcare for follow-up as appropriate. as part of our commitment to you and to the rest of the linkedin members, we will do our best to ensure that the content on the page remains positive. however, since we cannot monitor every post or conversation feed, we realize that the occasional objectionable posts will pop up just from time to time. therefore, the company reserves the right to remove any postings at i

Organization
Ge Healthcare Technologies Inc.
Employees
51000
CEO
Mr. Peter J. Arduini
Industry
Healthcare

Discover More

FAQs